title: Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.
abstract: Extensive clinical use and a series of clinical trials have shown that oxcarbazepine is a valuable antiepileptic drug for the treatment of adults and children with partial onset seizures both in initial monotherapy, for conversion to monotherapy and as adjunctive therapy. The clinically recommended titration scheme for all forms of therapy in adults is to start with 150 mg/day at night and to increase by 150 mg/day every second day until a target dose of 900-1200 mg/day is reached. If necessary, one can go faster and start with up to 600 mg/day and titrate with weekly increments of up to 600 mg/day. In children, treatment can be initiated with 8-10 mg/kg/day body weight in two to three divided doses. Dosage can be increased by 8-10 mg/kg/day in weekly increments if necessary for seizure control. Hyponatremia (serum sodium <125 mmol/l) can develop gradually during the first months of oxcarbazepine therapy in approximately 3% of patients with a previously normal serum sodium. However, there is no need to measure baseline serum sodium concentrations unless the patient has renal disease, is taking medication which may lower serum sodium levels (such as diuretics, oral contraceptives or nonsteroidal anti-inflammatory drugs) or--in rare cases--has clinical symptoms of hyponatremia. During oxcarbazepine maintenance therapy measurement of serum sodium levels should also be considered if medications known to decrease sodium levels are added or symptoms of hyponatremia develop. Oxcarbazepine does not appear to have any clinically notable effects on other safety parameters such as renal and liver function or haematological test results. In summary, oxcarbazepine is a safe and well tolerated antiepileptic drug for partial epilepsy.
authors.affiliation: Epilepsy Reseach Group, Goethestrasse 5, D-14163 Berlin, Germany. dbschmidt@t-online.de
authors.forename: D
authors.initials: D
authors.lastname: Schmidt
authors.forename: S
authors.initials: S
authors.lastname: Arroyo
authors.forename: M
authors.initials: M
authors.lastname: Baulac
authors.forename: M
authors.initials: M
authors.lastname: Dam
authors.forename: O
authors.initials: O
authors.lastname: Dulac
authors.forename: M L
authors.initials: ML
authors.lastname: Friis
authors.forename: R
authors.initials: R
authors.lastname: Kälviäinen
authors.forename: G
authors.initials: G
authors.lastname: Krämer
authors.forename: J
authors.initials: J
authors.lastname: van Parys
authors.forename: B
authors.initials: B
authors.lastname: Pedersen
authors.forename: R
authors.initials: R
authors.lastname: Sachdeo
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004828:Epilepsies, Partial / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000078330:Oxcarbazepine; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine